GlaxoSmithKline
The purpose of this study is to monitor pregnancies exposed to gepotidacin and to evaluate possible teratogenic effects or birthweight-lowering effects of this medication relative to the primary outcomes of major congenital malformations (MCMs) and small for gestational age (SGA), as well as to evaluate secondary maternal, fetal, and infant outcomes.
Inclusion Criteria: For Both cohorts: * Participants with aged 15 to 50 years * United States resident * Currently pregnant * Participants personally signed and dated informed consent document or, upon waiver of written consent by the relevant Institutional review board (IRB), verbal consent indicating that the participant (or a legally acceptable representative) has been informed of all pertinent aspects of the study * Authorization and contact information for the reporter (e.g., participant, maternal/infant Health care provider (HCP), prescriber) to allow for follow-up Exposed cohort: •…
Not Applicable since Observational Study
Not Applicable since Observational Study
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.